Li Kang Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	581.53	565.52	629.38	684.25	386.97	456.72
Revenue Growth (YoY)	1.42%	-10.15%	-8.02%	76.82%	-15.27%	-5.50%
Cost of Revenue	187.64	179.42	203.23	295.68	122.29	156.09
Gross Profit	393.89	386.1	426.15	388.58	264.68	300.64
Selling, General & Admin	298.5	296.08	292.77	251.22	207.44	219.71
Operating Expenses	298.5	296.08	292.77	251.22	207.44	219.71
Operating Income	95.39	90.02	133.37	137.36	57.25	80.93
Interest Expense	-0.17	-0.69	-0.62	-0.29	-0.46	-0.55
Interest & Investment Income	5.6	6.37	3.29	1.6	2.21	1.19
Currency Exchange Gain (Loss)	-0.75	0.64	0.02	0.96	-0.22	-0.6
Other Non Operating Income (Expenses)	2.61	2.58	2.19	3.35	1.69	1.7
EBT Excluding Unusual Items	102.66	98.91	138.25	142.98	60.48	82.66
Gain (Loss) on Sale of Investments	-0.33	0.28	0.9	-2.2	-1.75	-1.11
Gain (Loss) on Sale of Assets	-	-	-	-	-	0.01
Other Unusual Items	-	-	-	0.02	4.76	5.38
Pretax Income	102.34	99.19	139.14	140.8	63.48	86.94
Income Tax Expense	20.3	22.16	28.15	28.7	12.05	17.68
Net Income	82.04	77.02	110.99	112.09	51.44	69.27
Net Income to Common	82.04	77.02	110.99	112.09	51.44	69.27
Net Income Growth	0.06%	-30.61%	-0.98%	117.92%	-25.74%	-3.82%
Shares Outstanding (Basic)	32	31	27	27	27	27
Shares Outstanding (Diluted)	32	31	27	27	27	27
Shares Change (YoY)	6.78%	15.70%	-	0.10%	-0.23%	0.05%
EPS (Basic)	2.58	2.48	4.14	4.18	1.92	2.58
EPS (Diluted)	2.56	2.47	4.12	4.16	1.91	2.57
EPS Growth	-6.50%	-40.05%	-0.96%	117.46%	-25.49%	-3.73%
Free Cash Flow	-247.06	2.63	93.48	156.08	56.19	79.9
Free Cash Flow Per Share	-7.73	0.08	3.47	5.79	2.09	2.96
Dividend Per Share	2.000	2.000	2.500	1.739	1.242	2.319
Dividend Growth	-20.00%	-20.00%	43.75%	40.00%	-46.43%	40.00%
Gross Margin	67.73%	68.27%	67.71%	56.79%	68.40%	65.83%
Operating Margin	16.40%	15.92%	21.19%	20.07%	14.79%	17.72%
Profit Margin	14.11%	13.62%	17.64%	16.38%	13.29%	15.17%
Free Cash Flow Margin	-42.48%	0.46%	14.85%	22.81%	14.52%	17.49%
EBITDA	105.19	100.38	143.05	148.35	70.14	95.94
EBITDA Margin	18.09%	17.75%	22.73%	21.68%	18.12%	21.01%
D&A For EBITDA	9.8	10.36	9.68	10.99	12.89	15.02
EBIT	95.39	90.02	133.37	137.36	57.25	80.93
EBIT Margin	16.40%	15.92%	21.19%	20.07%	14.79%	17.72%
Effective Tax Rate	19.83%	22.35%	20.23%	20.39%	18.97%	20.33%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.